account_id none on file
legal_name Pliant Therapeutics, Inc.
ticker PLRX
cik 1746473
domain pliantrx.com
linkedin_company_url https://www.linkedin.com/company/pliant-therapeutics/
entry_point_account_id none on file
name Pliant Therapeutics Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 12 executives 2 family 0
why_nownone on file
callsnone on file
filings
As of December 31, 2025, the amount also included accrued severance costs of $ 2.5 million. 7. Long-term Debt In March 2024 we entered into an Amended and Restated Loan and Security Agreement (the “Amended Loan Agreement”) with Oxford Finance LLC (“Oxford”) to borrow a series of term loans up to an aggregate principal amount of $ 150.0 million.
filing / Aug 11, 2026 / receipt
The restructuring plan was completed in the third quarter of 2025 and amounted to $ 3.8 million. In December 2025, we initiated an additional restructuring plan totaling $ 2.5 million.
filing / Aug 11, 2026 / receipt
In addition, in 2025, we made the strategic decision to restructure our workforce and right-size the Company in order to reduce our costs, preserve cash reserves and prioritize efforts on PLN-101095.
filing / Aug 11, 2026 / receipt
The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services.
filing / Aug 11, 2026 / receipt
If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.
filing / Aug 11, 2026 / receipt
Though the Oyster Point Lease is accounted for as a single contract, the office space was occupied in March 2024 while the laboratory space was occupied in June 2024.
filing / Aug 11, 2026 / receipt
As of December 31, 2025, the amount also included accrued severance costs of $ 2.5 million. 7. Long-term Debt In March 2024 we entered into an Amended and Restated Loan and Security Agreement (the “Amended Loan Agreement”) with Oxford Finance LLC (“Oxford”) to borrow a series of term loans up to an aggregate principal amount of $ 150.0 million.
filing / May 11, 2026 / receipt
The restructuring plan was completed in the third quarter of 2025 and amounted to $ 3.8 million. In December 2025, we initiated an additional restructuring plan totaling $ 2.5 million.
filing / May 11, 2026 / receipt
As a result, we have made, and continue to make, strategic decisions to reduce our costs and preserve our cash reserves, including restructuring our workforce.
filing / May 11, 2026 / receipt
In addition, in 2025, we made the strategic decision to restructure our workforce and right-size the Company in order to reduce our costs, preserve cash reserves and prioritize efforts on PLN-101095.
filing / May 11, 2026 / receipt
If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.
filing / May 11, 2026 / receipt
Though the Oyster Point Lease is accounted for as a single contract, the office space was occupied in March 2024 while the laboratory space was occupied in June 2024.
filing / May 11, 2026 / receipt
executives
| David Pyott | director | - | receipt |
| Minnie Kuo | Chief Operating Officer | - | receipt |
familynone on file
upcoming
| 2026-11-05 | earnings call | scheduled | ir |
changes
mcp_package_hint
slug pliant-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$